PolyPid (PYPD) Cash & Current Investments (2019 - 2026)
PolyPid (PYPD) posted Cash & Current Investments of $9.1 million for Q1 2026, up 37.71% sequentially from $6.6 million in Q4 2025, and up 272.67% YoY from $2.4 million in Q1 2025.
PolyPid (PYPD) Cash & Current Investments (2019 - 2026) Analysis & Trends
PolyPid has reported Cash & Current Investments for 8 years, with the latest figure at $9.1 million in Q1 2026.
- Quarterly Cash & Current Investments rose 272.67% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 272.67% YoY) and the FY2025 annual result came in at $6.6 million, down 58.28% from the prior year.
- Cash & Current Investments rose to $9.1 million in Q1 2026 per PYPD's latest filing, from $6.6 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $17.6 million in Q2 2025 and troughed at $1.8 million in Q3 2023.
- A 5-year average of $8.4 million and a median of $6.9 million in 2023 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2023 and 2025: Cash & Current Investments tumbled 88.8% in 2023, then jumped 444.3% in 2025.
- Over 5 years, Cash & Current Investments stood at $9.1 million in 2022, then sank by 38.11% to $5.6 million in 2023, then jumped by 181.85% to $15.8 million in 2024, then plunged by 58.28% to $6.6 million in 2025, then jumped by 37.71% to $9.1 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $9.1 million, $6.6 million, and $9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 6.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.77 Mn |
| Mar 31, 2026 | 9.08 Mn |
| Dec 31, 2025 | 6.60 Mn |
| Sep 30, 2025 | 9.86 Mn |
| Jun 30, 2025 | 17.63 Mn |
| Mar 31, 2025 | 2.44 Mn |
| Dec 31, 2024 | 15.81 Mn |
| Sep 30, 2024 | 4.97 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 4.01 Mn |
| Dec 31, 2023 | 5.61 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Mar 31, 2023 | 6.87 Mn |
| Dec 31, 2022 | 9.06 Mn |
| Sep 30, 2022 | 16.50 Mn |
| Jun 30, 2022 | 13.01 Mn |
| Mar 31, 2022 | 11.83 Mn |
| Dec 31, 2021 | 10.22 Mn |
| Sep 30, 2021 | 9.61 Mn |